PAVING THE WAY FOR GROWTH

Autumn Conference – Cheuvreux

Paris, Thursday September 25th, 2008

Mr Jean-Luc Bélingard – Chief Executive Officer

Mrs Claire Giraut – Chief Financial Officer

Mr David Schilansky – Investor Relations Officer

DISCLAIMER

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

PROFILE AND STRATEGY

AN INNOVATION DRIVEN INTERNATIONAL SPECIALTY PHARMA

A strategic focus on specialist care worldwide	▪ Three targeted areas : Oncology, Endocrinology and Neuromuscular Disorders ▪ 5 key products accounting for ~ 57% of drug sales ▪ Growing at a double digit rate
A historic presence in primary care	▪ Focused on gastroenterology, cognitive disorders and cardiovascular diseases ▪ A presence focused on selected geographies including France, China and Russia ▪ A sound business yielding recurring cashflow and contributing to R&D financing
A truly differentiating and international R&D capability	▪ Focused on hormone-dependent diseases, peptide and protein engineering and innovative delivery systems ▪ R&D expense in excess of 20% of sales ▪ 4 centres in Boston, Paris, London and Barcelona
An integrated player	▪ A fully-fledged peptide manufacturing capability ▪ Two FDA-approved manufacturing facilities
A recognised strategic partner	▪ Alliances with international industry leaders in US, Europe and Japan and best-in-class universities around the world ▪ Ipsen's business partners include Galderma, Genentech, GTx, Medicis, Roche, Teijin…

JUNE 2008: IPSEN ANNOUNCES US ENTRY…

1. Agreement with Tercica Inc.'s Special Committee and Board of Directors to purchase the remainder of Tercica Inc.'s outstanding common stock

2. Agreement with Vernalis plc. to acquire its US operations and rights for Apokyn®

… IN LINE WITH ITS STRATEGY TO GROW AND GLOBALISE ITS SPECIALTY CARE BUSINESS

MISSION STATEMENT

To be a worldwide best-in-class provider of innovative drugs, addressing unmet medical needs in its targeted therapeutic areas

STRATEGIC PRIORITIES

❶ **GROW** top-line and profits in specialist care by providing innovative drug therapy

❷ **GLOBALIZE** through active geographical expansion policy

❸ **OPTIMIZE** returns of primary care through selected product life cycle management, partnerships and focused investments

3 botulinum toxin dossiers under review (US and Europe)	Add a companion product to Dysport® ✓	Somatuline® US sales ramp-up ✓	Choice of a commercialisation option for Dysport® in the US ✓	Adenuric® (febuxostat) partnership opportunities in Europe	Disclosure by Roche of GLP-1 (R1583) phase II results and phase III initiation ✓
Increlex® sales ramp up in Europe	Enrich R&D pipeline ✓	OBI-1 development optimisation ✓	Reloxin® filing in the US ✓		

A UNIQUE CONVERGENCE OF TECHNOLOGIES

2 examples:
Somatuline® and Taspoglutide

IPSEN
Innovation for patient care

SOMATULINE®: AN IMPROVED PHARMACOKINETIC PROFILE





	Sandostatin LAR®	Somatuline ® Autogel ®
Indications	**Acromegaly NET**	**Acromegaly NET (EU only)**
Administration route	Intramuscular	**Subcutaneous**
Volume injected	**2.0 ml**	**0.4 ml**
Needle length	**40mm**	**20mm**
Formulation	Powder for reconstitution	**Ready to use**

Comparison Of pre-filled (RHS) Versus competitor Intramuscular Injection device (LHS)

TASPOGLUTIDE® (GLP-1): LEVERAGING OUR TECHNOLOGICAL PLATFORMS

- Equal / greater potency compared to native compound
- Extended metabolic half-life: 22x more stable in plasma
- Complete retention of incretin properties
- Strong patent positions
- Once-a-week injection

FINANCIAL TERMS

- ~ €60 m paid upfront
- ~ €170 m potential additional milestones
- Mid-teens royalties on Roche's WW net sales

Designing the peptide itself…



Human GLP-1(7-36)NH2 is cleaved in plasma at both N- & C termini: modification of positions 8 & 35

…so that it fits Ipsen's innovative delivery systems technologies

Insulin type needle for subcutaneous injection



50 to 300µl of highly concentrated aqueous solution devoid of excipient

Example of a pre-filled delivery device presentation (eg. Preloaded pen injector)

SOMATULINE® AND DYSPORT®

Field proven products entering the world's largest market

LEADING FIELD-PROVEN PRODUCTS IN EUROPE…

Somatuline®	Dysport®
▪ Somatostatin analogue ▪ Highly differentiated product ▪ Main indications: acromegaly/NET ▪ Marketed in Europe since 1995 ▪ Approved in the US in August 07	▪ Botulinum Toxin of Type A ▪ Efficient and field proven product ▪ Main indication: dystonia, spasticity* ▪ Marketed in Europe since 1991 ▪ Under review by FDA since Jan.08

n°1 or n°2 in most markets where Ipsen operates

US entry through…	Proposed acquisition of Tercica Inc.	**Acquisition of** Vernalis plc's US operations, now **Ipsen Pharmaceuticals Inc.**

….now entering North America, the largest pharmaceutical market in the world

***cervical dystonia, cerebral palsy in children, muscle spasticity, blepharospasm/hemifacial spasm**

ACQUISITION OF TERCICA: WHY NOW?



Ipsen believes that it is now time to be fully responsible for the execution of the commercialisation of Somatuline® Depot in North America and for the development of promising R&D projects

ACQUISITION OF IPSEN PHARMACEUTICALS INC.: WHY NOW?

- Dysport® : a strong brand with well established positions
- Used globally for therapeutic indications: cervical dystonia, cerebral palsy in children, muscle spasticity, blepharospasm, hemifacial spasm
- Launched in the UK in 1991
- Marketing authorisations in over 70 countries (in Europe (including Russia), Asia and Latin America)
- Equivalent market share in therapeutic use to that of its main competitor in the 5 main European countries
- **Dysport® was filed for review by the FDA at the end of January 2008 for cervical dystonia**



2002 to 2005 are in French GAAP



Sales breakdown in 2007

Ipsen needs to prepare now for the US launch of Dysport®

WHY CHOOSE IPSEN PHARMA INC. TO LAUNCH DYSPORT® IN THE US?

A CNS focused company rightly sized to maximize the launch of Dysport®, with 54 staffs

A team with operational and therapeutic expertise and strong track-record

Strong managed healthcare experience, especially for injectable drugs

A relevant and targeted market reach, with largely similar prescriber base between Dysport® and Apokyn® - Vernalis Inc. today covers ~75% of US movement disorder specialists and neurologists

A sound commercial strategy
based on strong customer relationship and true value-added services provided to physicians

A lean organization, with no overlap with Ipsen's existing structures

A well positioned product on the market
Apokyn®, the only product indicated in the treatment of "off" episodes of Parkinson's disease

A reasonable investment
Total consideration of up to $12.5 million, and investment in Vernalis plc. for $5.0 million

A RICH R&D PIPELINE

A STRONG PIPELINE TO FUEL FUTURE GROWTH

NEW CHEMICAL ENTITIES

BN 83495 (STX 64)	Post-menopausal breast cancer	Phase I
BN 2629 (SJG-136)	Advanced metastatic cancers	Phase I completed
Diflomotecan (BN 80915)	Advanced metastatic cancers	Phase II
Elomotecan (BN 80927)	Advanced metastatic cancers	Phase I
Acapodene®	Treatment of Androgen Deprivation Therapy induced iatrogenic effects	Phase III completed
Taspoglutide (R1583)	Type 2 diabetes	Phase III
Dopastatin	Acromegaly /Neuro endocrine tumors	Phase I
OBI-1	**Haemostasis**	**Phase II completed**

LIFE CYCLE MANAGEMENT PROGRAMMES

Decapeptyl®	Pre-menopausal breast cancer	Phase III
Decapeptyl®	6 month SRF (prostate)	Phase III completed
Somatuline Autogel®	Non functioning neuro endocrine tumors	Phase III
Somatuline Autogel®	Co-administration with Pegvisomant	Phase III
Somatuline Depot	**Neuroendocrine tumors (US)**	**Phase III**
Dysport®	**Cervical Dystonia**	**Under regulatory review in the US**
Botulinum toxin A	Aesthetic medicine	Under regulatory review in the EU
Reloxin®	**Aesthetic medicine**	**Under regulatory review in the US**
Tanakan®	Mild cognitive impairment related to age	Phase III

Purple: Oncology / Green: Endocrinology / Blue: Neuromuscular disorders - In Bold: US projects
This table excludes pre-clinical projects

IPSEN AND TERCICA: AN UNRIVALLED ENDOCRINOLOGY PIPELINE



- A “global care solution” in growth disorders worldwide
- The strength of a single global voice in the market

Tercica:
A powerful commercial platform from which to launch future compounds

OUTLOOK

MAJOR KEY MILESTONES STILL AHEAD OF US…

MISSION STATEMENT

To be a worldwide best-in-class provider of innovative drugs, addressing unmet medical needs in its targeted therapeutic areas

STRATEGIC PRIORITIES

1. **GROW** top-line and profits in specialist care by providing innovative drug therapy
2. **GLOBALISE** through active geographical expansion policy
3. **OPTIMISE** returns of primary care through selected product life cycle management, partnerships and focused investments

- Botulinum toxin in aesthetic use under review in Europe
- Reloxin® under review in the US
- STX-64 phase I data
- Dopastatin phase I data
- Decapeptyl® and Acapodene® submissions
- Dysport® under review in the US
- OBI-1 end of phase II meeting with the FDA
- Choice of a commercialisation option for Dysport® in the US ✓
- Somatuline® phase III initiation in NET in the US
- Adenuric® (febuxostat) partnership opportunities in Europe
- Disclosure by Roche of GLP-1 Taspoglutide phase II results and phase III initiation ✓

A STRONG FIRST HALF 2008

Performance growth *

+11.2%

Specialty care sales growth

+13.4%

Reported operating margin
(in % of sales)

29.3%

Fully diluted EPS growth

+42.1%

NOTE: H1 2008/2007 growth rates

** Excluding Ginkor Fort® and at constant currency*

FULL YEAR 2008: STANDALONE FINANCIAL OUTLOOK

	2008 OLD objectives	2008 NEW objectives	2007 base
Sales growth	Underlying: 6.5 to 7.5% (1) Reported: 3.2 to 4.2%	Upper end of the range	€883.6 millions €920.5 millions
Other revenues growth	13.0 to 16.0% (2)	25.0 to 30.0%	€73.3 millions
Operating margin	22.0 to 23.0% (in % of sales)	23.0 to 24.0% (in % of sales)	22.7%

Ipsen will revise its full-year financial objectives once all transactions announced on June 5, 2008 are closed

NOTE 1 : excluding the sales of Ginkor Fort® in 2007 and 2008 and at constant currency
NOTE 2 : at constant currency

LONGER TERM OUTLOOK

2009	Sales growth: 12.0 to 14.0%[1] compared to Ipsen's standalone objectives for 2008
	Operating margin: around 15%[2] (in % of total sales)
A continued commitment to innovation, with a R&D expense of 19.0 to 21.0% of total sales	
Group operating margin expected to return to its 2007 level in 2011 [3]	
Creating a North American platform expected to generate sales in excess of $300 million in 2012[1] and potentially close to $1 billion by the end of the next decade	

NOTE 1: At constant exchange rate
NOTE 2: Before taking into account transaction-related recordings or purchase accounting impacts
NOTE 3: Excluding any assumption on GLP-1 potential future royalty stream

IPSEN TODAY….

- **Resilience of business** in a difficult macro-economic environment
- A strong and profitable specialty care **growth engine**
- **Substantial growth opportunities** through globalization and US entry
- A **rich and well balanced R&D pipeline**, with potential blockbusters
- A **strong cash flow generation and balance sheet**

FIRST HALF 2008 RESULTS

Appendix 1

SALES PERFORMANCE

Sales performance by therapeutic area



Sales performance by region



Acceleration of growth

NOTE (1): Excluding the full sales of Ginkor Fort ®
** Excluding the sales of Ginkor Fort® and at constant currency*

OTHER REVENUES EVOLUTION

Royalties received	▪ Stable Kogenate® royalties ▪ Carry-over of some royalties into 2007 and 2008
Milestone payments and licensing agreements	▪ Roche, Medicis and Recordati partnerships ▪ €13.7 m recognized in the context of the Ginkor® Fort divestment
Other revenues	▪ Revenues received in the context of a renewal of a co-promotion contract



A strong performance, notably with the success of the Ginkor Fort® divestment

GROSS MARGIN EVOLUTION

+ Continued productivity improvements despite an increase in some raw materials and energy costs

- Fast growing specialty care inducing a favorable “mix effect” more than offset by (i) fast growth of in-licensed products, (ii) strong growth of drug-related sales

- Some stock depreciations

- Negative FX impact

- Transfer of certain R&D costs to CoGS in connection with the progressive shift of a unit’s production from R&D to commercialization purposes

= Limited price cuts during the period



Fast growing in-licensed products, some stock depreciation and accounting shifts more than offset the mechanical positive mix effect

SG&A EXPENSES EVOLUTION

Other sales & marketing expenses

- Efficient containment of actionable Sales & Marketing expenses reflecting productivity improvements
- Seasonality of Sales & Marketing costs
- Strong increase in royalties paid to third parties partly offset by lower taxes on sales (notably in Spain)

General & Administrative expenses

- Efficient cost containment



Efficient cost containment and productivity improvements drive SG&A growth below sales growth level

R&D EXPENSES EVOLUTION

Drug-related R&D

Major research and development projects:

- Filing of Dysport® in the US
- Somatuline® in non-functioning NET
- Dopastatin phase I
- Sulfatase inhibitor (BN83495) phase I

Industrial development

- End of preparation for pre-approval FDA inspections in certain manufacturing sites in the context of the filing of Dysport® and Somatuline® Depot in the US
- Transfer of certain R&D costs to CoGS



A sustained effort in R&D
despite an expected decrease in Industrial development costs post US filings

OPERATING INCOME EVOLUTION

- Strong performance of all products
- Higher “other revenues”, notably with the success of the Ginkor Fort® divestment
- Strong sales of in-licensed products and drug related activities as well as stock depreciations weight on CoGS ratio
- Limited overall FX impact on operating income
- Productivity efforts in the context of the continued launch costs for Increlex® and Adrovance®



A strong operating performance
driven by a positive blend of business robustness and productivity efforts

FINANCIAL INCOME EVOLUTION

	H1 07	H1 08	Change
▪ Impact of Tercica convertibles and warrant conversion / exercise:	**€(2.2) m**	**€0.9 m**	**+€3.1 m**
- Increase of interests on convertible notes:	€0.7 m	€1.9 m	+€1.2 m
- Accelerated interests recognition on converts:	-	€8.3 m	+€8.3 m
- Fair value change on Tercica options and warrant:	€(1.5) m	€(6.3) m	- €4.7 m
- Exchange rate on Tercica convertibles and warrant:	€(1.4) m	€(3.1) m	- €1.6 m
▪ Impact from hedging on Tercica warrant and US operations:	**-**	**€(2.3) m**	**€(2.3) m**
▪ Additional income from cash/cash equivalents and others:	**€3.4 m**	**€4.8 m**	**+€1.4 m**
Total financial income	**€1.2 m**	**€3.4 m**	**+€2.2 m**



INCOME TAX EVOLUTION

- H1 2008 benefited from a change in the computation rules of tax credits on research expenses in France
- H1 2007 was negatively impacted by a reduction in the value of deferred tax assets in the Netherlands, following the cut in tax rate



NET INCOME AND EPS EVOLUTION





A strong overall performance

CASH FLOW GENERATION

(In million of euros)	30 June 07	30 June 08
Cash Flow before change in working capital	**112.6**	**141.3**
(Increase) / Decrease in working capital	(65.3)	(17.1)
Net cash flow generated by operating activities	**47.3**	**124.1**
Investment in intangible assets and property. plant & equipment	(30.0)	(38.4)
Deposits and other financial investments	(4.3)	-
Others	(12.1)	6.0
Net cash flow used in investing activities	**(46.4)**	**(32.4)**
Net change in borrowings	2.4	(4.6)
Dividends paid	(50.4)	(55.1)
Others	(18.7)	(5.2)
Net cash flow used in financing activities	**(66.8)**	**(64.9)**
Discontinued operations	2.2	(1.0)
Change in cash and cash equivalent	**(63.7)**	**25.8**
Impact of exchange rate fluctuations	-	(3.0)
Closing cash & cash equivalents	**220.0**	**263.7**
Closing Net Cash[(1)]	**198.4**	**239.4**

Comments

- **Increase of receivables (-€36.8m)**
- **Increase of tax payables (+€24,4m) vs significant decrease in H1 2007**
- **Capex required to maintain industrial facilities (-€26.2m)**
- **Intangible assets investment (-€8m)**
- **Revenues from Ginkor divestments (+€13.8m)**
- **Change in working capital linked to investing activities (-€12,6m)**
- **Sale of securities held for sale**
- **Share buy back program**

(1) Net cash: cash. cash equivalents and securities held for sales minus bank overdrafts. bank borrowings and other financial liabilities plus or minus derivative financial instruments

TERCICA'S MAIN IMPACTS ON IPSEN'S ACCOUNTS

(In thousand euros)	H1 2007	H1 2008
Convertible notes and warrant		
Change in fair value of warrant	(1 058)	(2 360)
– *Incl. Exchange rate impact*	*(89)*	*(491)*
Change in fair value of option	(609)	(4 944)
– *Incl. Exchange rate impact*	*(59)*	*(548)*
Exchange rate impact on notes w/o option	(1 278)	(1971)
Interests on convertible Notes	634	10 160
– *Incl. Exchange rate impact*	*(2)*	*(43)*
Impact on financial income	**(2 309)**	**885**
Corresponding income tax impact	**21**	**(42)**
Loss from associates	**(2 999)**	**(4 817)**
Purchase accounting	**(463)**	**(408)**
Loss from associates	**(3 462)**	**(5 225)**
Impact on Ipsen consolidated net profit	**(5 750)**	**(4 382)**

Comments

- Exercice/conversion date (July 22, 2008) taken into account in the valuation model
- $/€ exchange rate evolution
- Accelerated recognition due to early exercice/conversion date
- Reduced rate (1.7%)
- Share in Tercica loss (~25%)
- Net amortization of Increlex™

BALANCE SHEET EVOLUTION

(In million euros)

Assets

	31 Dec 07	30 Jun 08
Goodwill	189.0	189.0
Property, plants & equipments	221.9	226.6
Intangible assets	89.2	92.5
Other non-current assets	185.3	95.1
Total non-current assets	**685.4**	**603.2**
Total current assets	**636.8**	**744.6**
Incl. cash and cash equivalents	*247.1*	*269.7*
Assets / discontinued operations	0.7	-
Total assets	**1,322.9**	**1,347.9**
Net Cash (1)	**198.4**	**239.4**

(In million euros)

Liabilities

	31 Dec 07	30 Jun 08
Equity	799.9	844.1
Minority interests	1.2	1.4
Total equity	**801.1**	**845.5**
Long-term financial debts	20.8	16.3
Other non-current liabilities	221.0	223.0
Short-term debts	9.2	10.4
Other current liabilities	265.5	249.1
Liabilities / discontinued operations	5.3	3.6
Total Liabilities	**1,322.9**	**1,347.9**

(1) Net cash: cash, cash equivalents and securities held for sales minus bank overdrafts, bank borrowings and other financial liabilities plus or minus derivative financial instruments

MILESTONES CASHED IN BUT NOT YET RECOGNIZED AS REVENUES

(In million euros)	30 June 07	30 June 08
Payments not yet recognised as revenues in H2	8.3	11.2
Payments not yet recognised as revenues in Y+1	17.2	22.4
Payments not yet recognised as revenues in Y+2 and beyond	167.2	183.3
Total Milestones cashed in but not yet recognised as revenues	**192.7**	**216.9**

GAINING FULL CONTROL OF OBI-1'S DEVELOPMENT

Appendix 2

GAINING FULL CONTROL OVER A PROMISING COMPOUND

1. **Leveraging our know-how in haematology by gaining full rights to the product's development and commercialisation…**
   - Ipsen produced and commercialized the only plasma-derived porcine Factor VIII until 2004, Hyate:C
2. **… in order to fulfill a high unmet medical need…**
   - Acquired hemophilia is an orphan disease (prevalence of 1.5 per million): 6% to 22% of patients die from bleeding
3. **… and optimise its development and time to market…**
   - The development of OBI-1 will benefit from Ipsen's integrated approach and specific knowledge base in hemophilia A with inhibitor and plasma-derived porcine Factor VIII
4. **… for a highly specialized hospital product, generating high revenue per patient**
   - Potential peak sales worldwide in excess of $200 million

An incremental investment to gain full control of the development of a promising compound

TRANSACTION DETAILS

- **In 1998, Emory University licensed to Octagen its patents on OBI-1, who in turn granted a worldwide, exclusive sublicense to Ipsen**
  - Octagen was responsible for the pre-clinical and clinical development of OBI-1 and sublicensed certain rights to Ipsen in connection with the manufacturing, regulatory activities and commercialization of OBI-1.
  - Ipsen agreed to make milestone payments to Octagen and to pay royalties based on OBI-1 future net sales.
  - Ipsen purchased c.21.5% of Octagen's share capital

- **Ipsen to acquire all Octagen's assets related to OBI-1**
  - Upfront payment of $10.5 million (€6.8 million) to Octagen,
  - Mid single digit royalty on net sales (including that to Emory)
  - Potential additional payments contingent on entry of the product into P.III and on marketing approvals
  - Redemption of its stake in Octagen

A UNIQUE AGENT FOR THE EMERGENCY CARE OF ACQUIRED HEMOPHILIA

- **Incidence of this autoimmune disease on the increase with the ageing population**
- **Silent disease often revealed under elective or emergency surgery**
  - Uncontrollable bleed due to antibodies against patient's factor VIII
- **OBI-1 provides fast controllable dose-responsive formation of blood clots through the intrinsic pathway of coagulation**
  - Upon stabilization of hemostasis, patients are treated to full recovery (using Rituxan)
- **OBI-1 will benefit from a strong support from the hematology community built by Ipsen**
  - Ipsen produced and commercialized the only plasma-derived porcine Factor VIII until 2004
- **Ipsen will control all pre-clinical and clinical development activities**
  - OBI-1 development will benefit from this integrated approach and Ipsen's specific knowledge in hemophilia A with inhibitor and plasma-derived porcine Factor VIII
  - Ipsen will now seek to confirm next steps towards registration, in liaison with regulatory agencies, with first feedback expected in 2008

ROCHE'S ADA TASPOGLUTIDE DATA

Appendix 3

Taspoglutide provided significant reductions in A1c and FPG along with weight loss in diabetic patients

- Once-weekly 10 mg and 20 mg were most effective at achieving A1c targets, body weight, and FPG reductions
  - Approx 80% of patients achieved ADA (7%) A1c target following 8 weeks of treatment
  - Significant reductions in A1c and weight loss were achieved after only 8 weeks of treatment in patients inadequately controlled on metformin monotherapy
  - Addition of taspoglutide resulted in no increased risk of hypoglycemia than metformin alone
  - Fasting plasma glucose (FPG) reductions observed following the first injection
  - Safety and tolerability profile supports entry into phase III

Taspoglutide, the first investigational once-weekly, long-acting, human GLP-1 analogue, provided significant reductions in A1c and FPG as well as weight loss with an acceptable safety and tolerability profile for use in patients with type 2 diabetes

Main efficacy conclusion from the dose titration study (ADA presentation no. 10-OR)



Metformin combination study objectives were to characterize dose range, efficacy & safety of taspoglutide



July 2008

79 and 81% of patients treated with taspoglutide achieved ADA target A1c (≤7%)



July 2008

Taspoglutide provided significant A1c reductions over only eight weeks (from baseline)



Taspoglutide safely reduced A1c below 7.0% with more than 1%-point reduction after only eight weeks

* All taspoglutide doses were statistically significant ($p<0.0001$)

July 2008

Taspoglutide provided significant dose-related weight loss in only eight weeks (from baseline)



Taspoglutide provided significant dose-related weight loss in only eight weeks (from placebo)



Taspoglutide 20 mg once weekly provided a 2 kg weight loss in only eight weeks

* p=0.0035, + p<0.0001, ‡ p=0.0083

July 2008

Taspoglutide provided significant reductions in FPG in only eight weeks

Appreciable reductions seen by weeks 1-2



* p=0.0002, + p<0.0001

Placebo | 5 mg once weekly | 10 mg once weekly | 20 mg once weekly | 10 mg once every 2 weeks | 20 mg once every 2 weeks

July 2008

Taspoglutide safety profile

- As expected, the most common adverse event was transient, dose-related, mild-to-moderate nausea
  - Episodes of nausea tended to occur during the first day after administration
  - 18% placebo-adjusted incidence in 10 mg once-weekly group
- The frequency of vomiting in the groups that received taspoglutide once-weekly was similar to placebo
  - In most patients, vomiting occurred only once and resolved within one day
- Most cases of nausea and vomiting resolved spontaneously while treatment continued
- Addition of taspoglutide resulted in no increased risk of hypoglycemia than metformin alone
- No acute pancreatitis was observed in the phase II program

Safety and tolerability profile supports entry into phase III

Taspoglutide is an investigational once-weekly, long-acting human GLP-1 analogue for the treatment of T2D

- Significantly improves both A1c and FPG over only eight weeks
- Provides substantial weight loss in a dose-response fashion
- Additional phase II titration study confirmed the safety and tolerability of taspoglutide
- Efficacy, safety and tolerability profile supports entry into phase III

Data from this study shows that taspoglutide has the potential to be the first once weekly, long-acting human GLP-1 analogue

July 2008

Taspoglutide phase III program
Targeted and competitive

- Taspoglutide phase III program designed to confirm promising phase II data and generate competitive launch label
  - Head-to-head comparisons: Sitagliptin, exenatide, insulin glargine
  - Patient population: Treatment-naïve → multiple OADs
    - Add-on to metformin
- Based on phase II data, two taspoglutide doses will be tested in all phase III studies:
  - 10 mg once weekly
  - 10 mg once weekly for 1 month → up-titrate to 20 mg once weekly
- First-patient-in expected 2H 2008
- 6 month treatment period with follow-up extension phases

July 2008

Approximately 2,500 type 2 diabetic patients will be randomized into taspoglutide´s phase III program

Study	Study	Sample size	Background OAD
1	Monotherapy vs. placebo	330	Treatment-naïve
2	Taspoglutide vs. sitagliptin vs. placebo	630	Metformin
3	Taspoglutide vs. insulin glargine	990	Metformin
4	Taspoglutide vs. exenatide	990	Metformin, TZDs, or metformin + TZDs
5	Add-on to sulfonylurea (± metformin) vs. placebo	200	Sulfonylurea (+/- metformin)
6	Add-on to pioglitazone + metformin vs. placebo	330	Pioglitazone + metformin

July 2008

Taspoglutide's target product profile
Aiming for best-in-class

Taspoglutide's competitive profile

Competitor A (bid GLP-1)

Taspoglutide's competitive advantage:

- Human GLP-1 analogue
- Once weekly dosing
- Over-all better efficacy and tolerability

Competitor B (qd GLP-1)

Taspoglutide's competitive advantage:

- Once weekly dosing
- Potential for better efficacy
- Effective starting dose
- Simple titration regimen

Competitor C (qw GLP-1)

Taspoglutide's competitive advantage:

- Human GLP-1 analogue
- Auto injector device
- Ease of injection (needle size, no reconstitution)
- Effective starting dose
- Simple titration regimen

Taspoglutide: Aiming for best-in-class